Pharmaceutical Technology on MSN3d
Ionis and Sobi agree on olezarsen commercialisation
As the European commercialisation partner of Ionis for Waylivra (volanesorsen), Sobi is set to utilise its current market ...
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...
Arrowhead Pharmaceuticals Is Finally Arriving
Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...
Ionis Pharmaceuticals enters exclusive olezarsen license agreement with Sobi
Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...
Investing4d
Ionis licenses olezarsen to Sobi for global reach
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.1 billion market cap biotechnology company currently trading near its 52-week low, has announced a licensing agreement granting Sobi® exclusive rights ...
pharmaphorum1y
Ionis preps filings for olezarsen in rare disease FCS
Ionis Pharma is preparing to file for regulatory approval of its experimental therapy olezarsen for familial chylomicronaemia syndrome (FCS) in the US and Europe after the drug met its targets in ...
Yahoo Finance5d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis will continue to independently commercialize olezarsen in the U.S. Olezarsen was approved by the FDA in December 2024 under the tradename TRYNGOLZA™ as an adjunct to diet to reduce ...
Morningstar5d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement ...
Seeking Alpha4d
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Ionis Pharmaceuticals (NASDAQ:IONS) has entered into a license agreement under which Sobi receives exclusive rights in countries outside the U.S., Canada and China to commercialize olezarsen as a ...